195 related articles for article (PubMed ID: 7514177)
1. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
Sliwkowski MX; Schaefer G; Akita RW; Lofgren JA; Fitzpatrick VD; Nuijens A; Fendly BM; Cerione RA; Vandlen RL; Carraway KL
J Biol Chem; 1994 May; 269(20):14661-5. PubMed ID: 7514177
[TBL] [Abstract][Full Text] [Related]
2. Activation of EGF receptor family members suppresses the cytotoxic effects of tumor necrosis factor-alpha.
Hoffmann M; Schmidt M; Wels W
Cancer Immunol Immunother; 1998 Nov; 47(3):167-75. PubMed ID: 9829842
[TBL] [Abstract][Full Text] [Related]
3. Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene.
Buxbaum JD; Georgieva L; Young JJ; Plescia C; Kajiwara Y; Jiang Y; Moskvina V; Norton N; Peirce T; Williams H; Craddock NJ; Carroll L; Corfas G; Davis KL; Owen MJ; Harroch S; Sakurai T; O'Donovan MC
Mol Psychiatry; 2008 Feb; 13(2):162-72. PubMed ID: 17579610
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer.
Steele TM; Tsamouri MM; Siddiqui S; Lucchesi CA; Vasilatis D; Mooso BA; Durbin-Johnson BP; Ma AH; Hejazi N; Parikh M; Mudryj M; Pan CX; Ghosh PM
Sci Rep; 2023 Jun; 13(1):9617. PubMed ID: 37316561
[TBL] [Abstract][Full Text] [Related]
5. Transcriptionally inducible Pleckstrin homology-like domain, family A, member 1, attenuates ErbB receptor activity by inhibiting receptor oligomerization.
Magi S; Iwamoto K; Yumoto N; Hiroshima M; Nagashima T; Ohki R; Garcia-Munoz A; Volinsky N; Von Kriegsheim A; Sako Y; Takahashi K; Kimura S; Kholodenko BN; Okada-Hatakeyama M
J Biol Chem; 2018 Feb; 293(6):2206-2218. PubMed ID: 29233889
[TBL] [Abstract][Full Text] [Related]
6. Coordinate transcriptional regulation of ErbB2/3 by C-terminal binding protein 2 signals sensitivity to ErbB2 inhibition in pancreatic adenocarcinoma.
Chougoni KK; Park H; Damle PK; Mason T; Cheng B; Dcona MM; Szomju B; Dozmorov MG; Idowu MO; Grossman SR
Oncogenesis; 2023 Nov; 12(1):53. PubMed ID: 37949862
[TBL] [Abstract][Full Text] [Related]
7. Targeting tumor cell destruction with CD64-directed bispecific fusion proteins.
Graziano RF; Goldstein J; Sundarapandiyan K; Somasundaram C; Keler T; Deo YM
Cancer Immunol Immunother; 1997; 45(3-4):124-7. PubMed ID: 9435854
[No Abstract] [Full Text] [Related]
8. Trans-activating mutations of the pseudokinase ERBB3.
Koivu MKA; Chakroborty D; Airenne TT; Johnson MS; Kurppa KJ; Elenius K
Oncogene; 2024 May; ():. PubMed ID: 38806620
[TBL] [Abstract][Full Text] [Related]
9. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch C; Weiss FU; Niederfellner G; Jallal B; Issing W; Ullrich A
EMBO J; 1995 Sep; 14(17):4267-75. PubMed ID: 7556068
[TBL] [Abstract][Full Text] [Related]
10. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor.
Tzahar E; Waterman H; Chen X; Levkowitz G; Karunagaran D; Lavi S; Ratzkin BJ; Yarden Y
Mol Cell Biol; 1996 Oct; 16(10):5276-87. PubMed ID: 8816440
[TBL] [Abstract][Full Text] [Related]
11. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran D; Tzahar E; Beerli RR; Chen X; Graus-Porta D; Ratzkin BJ; Seger R; Hynes NE; Yarden Y
EMBO J; 1996 Jan; 15(2):254-64. PubMed ID: 8617201
[TBL] [Abstract][Full Text] [Related]
12. Targeted Hyperbranched Nanoparticles for Delivery of Doxorubicin in Breast Cancer Brain Metastasis.
Lim M; Fletcher NL; Saunus JM; McCart Reed AE; Chittoory H; Simpson PT; Thurecht KJ; Lakhani SR
Mol Pharm; 2023 Dec; 20(12):6169-6183. PubMed ID: 37970806
[TBL] [Abstract][Full Text] [Related]
13. Structure and dynamics of the EGFR/HER2 heterodimer.
Bai X; Sun P; Wang X; Long C; Liao S; Dang S; Zhuang S; Du Y; Zhang X; Li N; He K; Zhang Z
Cell Discov; 2023 Feb; 9(1):18. PubMed ID: 36781849
[TBL] [Abstract][Full Text] [Related]
14. Unmyelinated sensory neurons use Neuregulin signals to promote myelination of interneurons in the CNS.
Lysko DE; Talbot WS
Cell Rep; 2022 Nov; 41(7):111669. PubMed ID: 36384112
[TBL] [Abstract][Full Text] [Related]
15. An effective strategy for ligand-mediated pulldown of the HER2/HER3/NRG1β heterocomplex and cryo-EM structure determination at low sample concentrations.
Trenker R; Diwanji D; Verba KA; Jura N
Methods Enzymol; 2022; 667():633-662. PubMed ID: 35525557
[TBL] [Abstract][Full Text] [Related]
16. EGFR Signaling in Lung Fibrosis.
Schramm F; Schaefer L; Wygrecka M
Cells; 2022 Mar; 11(6):. PubMed ID: 35326439
[TBL] [Abstract][Full Text] [Related]
17. Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells.
Stern YE; Al-Ghabkari A; Monast A; Fiset B; Aboualizadeh F; Yao Z; Stagljar I; Walsh LA; Duhamel S; Park M
Cell Mol Life Sci; 2022 Mar; 79(3):178. PubMed ID: 35249128
[TBL] [Abstract][Full Text] [Related]
18. Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases.
Lim M; Nguyen TH; Niland C; Reid LE; Jat PS; Saunus JM; Lakhani SR
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158800
[TBL] [Abstract][Full Text] [Related]
19. Heregulin Activity Assays for Residual Testing of Cell Therapy Products.
Monje PV; Bacallao K; Aparicio GI; Lalwani A
Biol Proced Online; 2021 Nov; 23(1):22. PubMed ID: 34772336
[TBL] [Abstract][Full Text] [Related]
20. Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface.
Diwanji D; Trenker R; Thaker TM; Wang F; Agard DA; Verba KA; Jura N
Nature; 2021 Dec; 600(7888):339-343. PubMed ID: 34759323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
